• Results
  • Licensing and IP management: Are companies engaging in voluntary licensing...
Licensing and IP management

Are companies engaging in voluntary licensing to expand access?

Management of the intellectual property (IP) of large R&D-based pharmaceutical companies impacts the availability and affordability of medicines. Enabling generic medicine manufacturers to develop generic versions of medicines can increase affordability, support supply, foster competition and ultimately improve access. A non-exclusive voluntary licence is an important approach, among many, to making a product accessible. 

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |